Quick Answer
Keros Therapeutics, Inc. reported Total Revenue of $244.06 million for fiscal year 2025.
Keros Therapeutics, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $244.06M +6775.0% |
$3.55M +2251.0% |
$151.0K | $0.00 -100.0% |
$20.10M | $0.00 -100.0% |
| Revenue (ASC 606) | $244.06M +6775.0% |
$3.55M +2251.0% |
$151.0K | $0.00 -100.0% |
$20.10M | $0.00 -100.0% |
| Net Income | $87.01M +146.4% |
-$187.35M -22.5% |
-$152.99M -46.2% |
-$104.68M -78.2% |
-$58.74M -29.5% |
-$45.36M -267.7% |
| Diluted EPS | $2.30 +146.0% |
-$5.00 +3.8% |
-$5.20 -25.3% |
-$4.15 -64.7% |
-$2.52 +14.0% |
-$2.93 |
| Total Assets | $338.02M -45.1% |
$615.89M +66.4% |
$370.02M +20.6% |
$306.78M +20.2% |
$255.25M -5.3% |
$269.44M +2359.5% |
| Cash and Equivalents | $287.42M -48.7% |
$559.93M +69.1% |
$331.15M +18.7% |
$279.05M +21.3% |
$230.04M -13.5% |
$265.88M +3687.4% |
| Stockholders Equity | $303.13M -47.0% |
$571.55M +72.0% |
$332.21M +19.7% |
$277.42M +14.1% |
$243.17M -7.1% |
$261.72M +1445.9% |
| R&D Expense | $129.64M -25.3% |
$173.63M +28.4% |
$135.26M +55.0% |
$87.27M +58.3% |
$55.14M +62.9% |
$33.86M +94.8% |
| Operating Income | $67.57M +132.0% |
-$210.83M -24.1% |
-$169.94M -48.0% |
-$114.79M -103.6% |
-$56.37M -20.8% |
-$46.66M -341.7% |
| Shares Outstanding | 19.54M -51.8% |
40.55M +27.4% |
31.84M +15.6% |
27.54M +14.9% |
23.97M +3.4% |
23.19M +854.6% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $14.26M | +3575.8% | -21.5% |
| Revenue (ASC 606) | September 30, 2025 | $14.26M | +3575.8% | -21.5% |
| Net Income | September 30, 2025 | -$7.28M | +86.3% | +76.3% |
| Diluted EPS | September 30, 2025 | -$0.18 | +87.2% | +76.3% |
| Total Assets | September 30, 2025 | $742.78M | +28.2% | -1.9% |
| Cash and Equivalents | September 30, 2025 | $693.47M | +30.7% | +0.5% |
| Stockholders Equity | September 30, 2025 | $703.58M | +32.0% | -0.4% |
| R&D Expense | September 30, 2025 | $19.52M | -60.3% | -55.1% |
| Operating Income | September 30, 2025 | -$15.38M | +73.8% | +61.4% |
| Shares Outstanding | September 30, 2025 | 40.63M | +3.5% | +0.0% |
- Keros Therapeutics, Inc. reported Total Revenue of $244.06 million for fiscal year 2025.
- Keros Therapeutics, Inc. showed an increase of +6775.0% in Total Revenue compared to the prior fiscal year.
- Keros Therapeutics, Inc. reported Revenue (ASC 606) of $244.06 million for fiscal year 2025.
- Keros Therapeutics, Inc. showed an increase of +6775.0% in Revenue (ASC 606) compared to the prior fiscal year.
- Keros Therapeutics, Inc. reported Net Income of $87.01 million for fiscal year 2025.
- Keros Therapeutics, Inc. showed an increase of +146.4% in Net Income compared to the prior fiscal year.
- Keros Therapeutics, Inc. reported Diluted EPS of $2.30 per share for fiscal year 2025.
- Keros Therapeutics, Inc. showed an increase of +146.0% in Diluted EPS compared to the prior fiscal year.
- Keros Therapeutics, Inc. reported Total Assets of $338.02 million for fiscal year 2025.
- Keros Therapeutics, Inc. showed a decrease of -45.1% in Total Assets compared to the prior fiscal year.
- Keros Therapeutics, Inc. reported Cash and Equivalents of $287.42 million for fiscal year 2025.
- Keros Therapeutics, Inc. showed a decrease of -48.7% in Cash and Equivalents compared to the prior fiscal year.
- Keros Therapeutics, Inc. reported Stockholders Equity of $303.13 million for fiscal year 2025.
- Keros Therapeutics, Inc. showed a decrease of -47.0% in Stockholders Equity compared to the prior fiscal year.
- Keros Therapeutics, Inc. reported R&D Expense of $129.64 million for fiscal year 2025.
- Keros Therapeutics, Inc. showed a decrease of -25.3% in R&D Expense compared to the prior fiscal year.
- Keros Therapeutics, Inc. reported Operating Income of $67.57 million for fiscal year 2025.
- Keros Therapeutics, Inc. showed an increase of +132.0% in Operating Income compared to the prior fiscal year.
- Keros Therapeutics, Inc. reported Shares Outstanding of 19.54 million shares for fiscal year 2025.
- Keros Therapeutics, Inc. showed a decrease of -51.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: